Applications of novel vaccines to immotherapy of food allergy by Akdis, Mübeccel
INVITED SPEAKER PRESENTATION Open Access
Applications of novel vaccines to immotherapy
of food allergy
Mübeccel Akdis
From Food Allergy and Anaphylaxis Meeting 2011
Venice, Italy. 17-19 February 2011
Allergic diseases including atopic dermatitis (AD), food
allergy, allergic rhinitis, asthma and anaphylaxis have
significant associated morbidity along with large health-
care expenditures. Food allergies are caused by immune
responses to food proteins and represent a breakdown
of oral tolerance. They can range from mild pruritus to
life-threatening anaphylaxis. The only treatment is food
avoidance, which might cause near-fatal and fatal reac-
tions by accidental exposures. For this reason, there has
been recent interest in immunotherapy, which may
induce desensitization and even tolerance. Through
these effects, immunotherapy may decrease the potential
for adverse serious reactions with accidental ingestions.
Therefore, it is expected that immunotherapy may be
adopted as the first treatment to modify the natural his-
tory of food allergy.
Allergen-specific immunotherapy (SIT) has been used
as a desensitizing therapy for allergic diseases and may
represents a curative and specific way of the treatment.
However, current allergen-SIT has several disadvantages
related to the content of the vaccine, type of adjuvant,
route of application, long duration time, side effects, and
sometimes limited efficacy. Immune system behaves in a
different way to extracellular pathogens as bacteria and
parasites. Initially capture of exogenous pathogen by
dendritic cell results in phagocytosis, which is then fol-
lowed by migration to local lymph nodes through che-
motactic signals where DCs maturate and lose
phagocytic capacity and improve antigen presentation
capacity to T cells. In T cell activation, several signals
are essential for the differentiation of naive T cells to
cytokine-producing effector Th cells. After the discovery
of regulatory T cells the concepts of immune regulation
have substantially changed during the last decade.
Peripheral T-cell tolerance is a key immunologic
mechanism in healthy immune response to self-antigens
and non-infectious non–self-antigens. Both naturally
occurring CD4+CD25+ regulatory T (Treg) cells and
inducible populations of allergen-specific, IL-10-secret-
ing Treg type 1 cells contribute to the control of aller-
gen-specific immune responses in several ways:
suppression of antigen-presenting cells that support the
generation of effector Th2 and Th1 cells; suppression of
Th2 and Th1 cells; suppression of mast cells, basophils
and eosinophils; interaction with resident tissue cells
and remodeling. In addition to the above mechanisms,
Tr1 and CD4+CD25+ Treg cells suppress IgE and
induce the noninflammatory antibody isotype IgG4.
As a novel approach, direct vaccine administration
into lymph nodes and targeting the MHC class II anti-
g e np r e s e n t a t i o np a t h w a yh a sb e e nh y p o t h e s i z e dt o
increase the immunogenicity, efficacy and the safety of
immunotherapy because of low allergen dose, however
better presented to T cells. The major cat dander aller-
gen Fel d 1 was fused to a TAT-derived protein translo-
cation domain and to a truncated invariant chain
(MAT-Fel d 1). This MAT-Fel d 1 vaccine is efficiently
internalized by APCs and induces IL-10 and IFN-g
dominated response, but low Th2 cytokines’ production
in PBMCs of allergic individuals. In a double-blind pla-
cebo-controlled clinical trial, MAT-Fel d 1 vaccine
adsorbed to alum was administered by 3 intralymphatic
injections in increasing dose (1 µg, 3 µg, 10 µg) into
inguinal, subcutaneous lymph node within 2 months
with 4 weeks intervals. Cat allergic patients became tol-
erant to nasal challenge with cat dander after only 3
injections. The blood for cell cultures have been taken
before the therapy and twice after finishing the treat-
ment: one week and one year respectively. Fel d 1-speci-
fic T cell tolerance was observed in the MAT-Fel d 1
group compared to placebo group after one year and
the significant enhancement of IL-10 production
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specific IgG4 in plasma samples. In addition, we
observed tendency of increase in Fel d 1-specific CD3
+CD4+FOXP3+ T cells’ number in MAT-Fel d 1 treated
patients using MHC class II peptide tetramers. Specific
IgE production however rose during ILIT but it was
contrary to the lack of drug related side effects. These
data demonstrate that intralymphnode administration of
MAT-Fel d 1 induces allergen-specific immune toler-
ance in cat allergic patients.
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